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Summary
Objective: To update our earlier systematic review which evaluated all published randomized controlled trials (RCTs) evaluating pharmaco-
logical and non-pharmacological therapies in patients with hand osteoarthritis (OA). Surgical therapies were not evaluated.
Method: RCTs published between August 2004 and February 2008 were added to the original systematic review.
Results: A total of 44 RCTs evaluating various pharmacological and non-pharmacological therapies in hand OA were analyzed in this update.
Generally, these RCTs were of low quality. RCTs were weakened by a lack of consistent case deﬁnition and by a lack of standardized out-
come assessments. The methods used for randomization, blinding, and allocation concealment were rarely described. The number and lo-
cation of symptomatic hand joints per treatment group at baseline was usually not stated. The number and location of evaluated hand
joints at the end of the study was also usually not stated. A meta-analysis could not be performed since most of the treatments studied
did not have more than one identical comparison to allow pooling of the data.
Conclusions: It is apparent that hand OA is a more complex area in which to study the efﬁcacy of therapies when compared to hip and knee
OA. The recently published OARSI Consensus Recommendations will improve the design and conduct of future RCTs in hand OA.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Therapy for hand osteoarthritis (OA) has received relatively
little attention when compared to OA of the hip and knee.
The objective of this paper is to update our previous version
of the systematic review of therapies for OA of the hand by
adding randomized controlled trials (RCTs) published
between August 2004 and February 20081.Criteria for inclusion and exclusion
The inclusion and exclusion criteria were identical to
those used in the original version of the systematic review.
RCTs evaluating surgical therapies were not included. We
included RCTs evaluating OA at multiple sites only if efﬁ-
cacy data were presented separately for the hand.Search strategy and study identiﬁcation
The following electronic data sources were searched for
this updated version of the systematic review: (1) MEDLINE
(1966 to February week 4, 2008), (2) PREMEDLINE (Feb-
ruary week 4, 2008), (3) EMBASE (1980 to February
week 4, 2008), (4) AMED (1985 to February week 4,
2008), (5) CINAHL, Allied Health (1982 to February week*Address correspondence and reprint requests to: Tanveer E.
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12634, 2008), (6) EBM Reviews, including the Cochrane Data-
base of Systematic Review (CDSR), the Database of Ab-
stracts of Reviews of Effectiveness (DARE), ACP Journal
Club and the Central Cochrane Database (1980 to February
week 4, 2008). Reference lists of all retrieved articles were
also manually searched. The ﬂow chart summarizing study
identiﬁcation and retrieval is shown in Fig. 1. The search
strategy used in MEDLINE was identical to that used in
the earlier version of this review.Methods
A data abstraction form was used to extract information pertaining to trial
demographics, methodology, quality, and outcomes2,3. Study quality was
evaluated by using Jadad’s scoring checklist4. The ﬁnal score ranges from
0 to 5, with a higher score reﬂecting higher methodological quality. Data ab-
straction was conducted by the two authors, independently. Results were
cross-checked for reliability and differences were resolved by reaching con-
sensus. Allocation concealment was speciﬁcally evaluated for each RCT.
A formal meta-analysis will be performed, if feasible.ResultsOVERVIEW OF STUDY DEMOGRAPHICSA total of 44 RCTs were analyzed in this systematic re-
view5e47 (Tables IeIII). Two RCTs were published in the
1970s, ﬁve were published in the 1980s, 14 were published
in the 1990s and 23 were published in the year 2000 or be-
yond. Thirty-six RCTs were available as English full paper
reports, four were non-English reports with English ab-
stracts, and four were only available as English abstracts.
• All citations identified and screened (n=819)
• Citations considered potentially relevant (n=184)
• Citations excluded from systematic review (n=32)
(see text)
• RCTs meeting inclusion criteria of systematic
review (n=44) 
Fig. 1. Flow chart of search strategy.
1264 D. Mahendira and T. E. Towheed: Systematic review of hand OA trialsThirty-two reports evaluating therapies in hand OA were
excluded from this review since they did not meet one or
more of the stated inclusion criteria of this systematic
review48e79.
Symptom modifying therapy was evaluated in 39 RCTs,
whereas a structural modifying therapy was evaluated in
three RCTs5,19. Two RCTs evaluated both a symptom mod-
ifying as well as a structural modifying therapy11,18. A paral-
lel, independent group study design was used in 35 RCTs
and a cross-over design was used in nine RCTs. The me-
dian number of subjects randomized per study was 41,
with a range of 5e910. The median number of subjects
completing the trials was 35, with a range of 5e559.
The median duration of the RCTs was 8.6 weeks, with
a range of 2 he260 weeks. Eighty-two percent of the sub-
jects randomized were female. The mean age of random-
ized subjects in the RCTs was 62.3 years, with a range of
53e82 years. Subjects had a mean duration of OA hand
symptoms of 6.1 years, with a range of 2e10.2 years.Table
Published RCTs in OA o
Study (authors and year) Groups N
rando
Thorpe, 19708 Fiorinal vs FIPA vs placebo 1
Swezey et al., 197928 Pressure glove vs control glove
vs no glove
Seiler, 198313 Meclomen vs placebo 4
Talke et al., 198532 Topical etofenamate vs oral
indomethacin
N
Basford et al., 198723 Helium neon laser vs placebo 8
Caruso et al., 198733 SAMey vs naproxen vs placebo 5
Pastinen et al., 19887 Glycosaminoglycan polysulfate
(GAGPS) IAz vs placebo
3
McCarthy and McCarty, 199226 Capsaicin vs placebo 1
Dreiser et al., 199315 Ibuprofen vs placebo 6
Verbruggen and Veys, 199319 GAGPS (IM)x vs placebo 9
Flynn et al., 199422 Folate vs folateþB12 vs placebo 3
Garﬁnkel et al., 199425 Yoga vs no therapy 2
Rothacker et al., 19946 Trolamine salicylate vs placebo 5
Schnitzer et al., 199417 Capsaicin vs placebo 5
Dougados and Nguyen, 199521 Topical niﬂumic acid vs placebo 1
Thiesce and Dougados, 199520 Topical diclofenac vs placebo 2
*NA¼ not available.
ySAMe¼ S-adenosylmethionine.
zIA¼ intra-articular.
xIM¼ intra-muscular.Five RCTs had an open follow-up period after study
discontinuation. Twenty-seven of the 44 RCTs (61%) had
a placebo group/arm. Seven RCTs were multi-centre. The
country of origin was heterogeneous with the US having
the greatest number of RCTs (14), followed by France (5),
Germany (5), Austria (3), Belgium (3), and Italy (3).
Nine RCTs had an oral non-steroidal anti-inﬂammatory
drug (NSAID) treatment group/arm. The individual NSAIDs
evaluated were: ibuprofen, naproxen, meclofenamate, rofe-
coxib, lumiracoxib and indomethacin. Seven RCTs had
a topical NSAID treatment group/arm. The individual topical
NSAID preparations evaluated were: topical ibuprofen, top-
ical etofenamate, topical diclofenac, and topical niﬂumic
acid. Two RCTs had a topical ASA group/arm. Both studies
evaluated topical trolamine salicylate in comparison to a pla-
cebo. Four studies evaluated intra-articular steroid use,
while four studies examined intra-articular hyaluronan.
Seven RCTs evaluated occupational therapy interventions.
These included the following: joint protection exercises,
splints of various kinds and technical accessories. Other ac-
tive agents tested included: capsaicin cream (2), glycosami-
noglycan polysulfate (GAGPS) (2) and chondroitin sulfate
(2). Several RCTs evaluated unconventional OA therapies,
such as: laser therapy (2), folate and cobalamin vitamin
therapy (1), leeches (1), tiled stove (1), TENs (1), yoga
(1), dextrose prolotherapy (1), pressure gradient gloves
(1), spa therapy (1), stinging nettle leaf (1), ﬁorinal of (1)
and hydroxychloroquine (1).FEATURES SPECIFIC TO HAND OA TRIALSNo consistent deﬁnition of hand OA was used in these
RCTs. Most trials (N¼ 32) did not explicitly distinguish be-
tween primary (idiopathic) and secondary OA. Ten RCTs
evaluated exclusively subjects with primary hand OA. One
RCT enrolled subjects with both primary and secondary
hand OA. Erosive hand OA was studied exclusively in twoI
f the hand (N¼ 44)
mized
N
completed
Design Duration
(weeks)
Overall efﬁcacy
0 9 Cross-over 6 (Fiorinal¼ FIPA)> placebo
5 5 Cross-over 6 Equal
1 22 Parallel 4 Meclomen> placebo
A* NA* Parallel 3 Equal
1 81 Parallel 3 Equal
1 NA* Parallel 4 Equal
0 29 Parallel 52 GAGPS> placebo
4 14 Parallel 4 Capsaicin> placebo
0 54 Parallel 2 Ibuprofen> placebo
2 68 Parallel 260 GAGPS> placebo
0 26 Cross-over 24 FolateþB12>
(placebo¼ folate)
6 25 Parallel 10 Yoga> no therapy
0 49 Cross-over NA* Trolamine> placebo
9 48 Parallel 9 Capsaicin> placebo
86 186 Parallel 1 Equal
0 20 Cross-over 1.5 Equal
Table II
Published RCTs in OA of the hand (N¼ 44)
Study (authors and year) Groups N
randomized
N
completed
Design Duration
(weeks)
Overall efﬁcacy
Renklitepe et al., 199531 Tens electrode glove vs carbon electrode 36 NA* Parallel 0.7 Glove electrode> carbon
electrode
Punzi et al., 199634 Hydroxychloroquine (HQ)
vs NSAID/analgesics
15 15 Parallel 52 HQ>NSAIDþ analgesic
Graber-Duvernay
et al., 199729
Berthollet spa vs topical ibuprofen 116 107 Parallel 24 Spa> ibuprofen
Rothacker et al., 199814 Trolamine salicylate vs placebo 86 81 Parallel 0.01 Trolamine> placebo
Buurke et al., 199912 Uriel splint vs sporlastic splint
vs gibortho splint
10 10 Cross-over 12 Uriel splint> others
Reeves and
Hassanein, 200011
Dextrose prolotherapy (DP) vs placebo 27 25 Parallel 24 DP> placebo
Weiss et al., 20009 Short splint vs long splint vs no splint 26 26 Cross-over 2 Short splint> long splint>
no splint
Randall et al., 200016 Stinging nettle leaf vs placebo 27 24 Cross-over 12 Stinging nettle
leaf> placebo
Berggren et al., 200110 OT vs OTþ textile splint vs
OTþ leather splint
33 33 Parallel 28 All groups had less hand
surgery
Zacher et al., 200130 Topical diclofenac vs oral ibuprofen 321 NA* Parallel 3 Equal
Stamm et al., 200227 Joint protection and exercise
(JPE) vs info only
40 40 Parallel 12 JPE> info only
Verbruggen et al., 20025 Chondroitin polysulfate (CPS) vs placebo 130 92 Parallel 156 CPS> placebo
Verbruggen et al., 20025 Chondroitin sulfate (CS) vs placebo 92 73 Parallel 156 CS> placebo
Lisse et al., 200324 Rofecoxib vs naproxen 910 NA* Parallel 12 Equal
Rovetta et al., 200418 CS and naproxen vs naproxen alone 24 24 Parallel 104 CSþ naproxen>
naproxen alone
*NA¼ not available.
1265Osteoarthritis and Cartilage Vol. 17, No. 10RCTs18,34. Only 11 RCTs used a validated hand OA classi-
ﬁcation scheme for study entry. These 11 studies used the
ACR classiﬁcation criteria80. Most often, hand OA was de-
ﬁned by the authors themselves with descriptions that
lacked sufﬁcient detail and precision (N¼ 23 RCTs). Radio-
graphs were taken at baseline in 24 RCTs. However, de-
tailed X-ray criteria were explicitly stated in only 16 of
these 24 RCTs.
The distribution of affected hand OA joints was quite
variable and was also inconsistently presented in the trial
reports. For example, 11 RCTs did not specify which joints
were being evaluated in the hand. Twelve RCTs evaluated
exclusively subjects with ﬁrst carpal metacarpal jointTable I
Published RCTs in OA o
Study (authors and year) Groups
r
Grifka et al., 200435 Lumiracoxib vs placebo
Leﬂer et al., 200436 Strength training exercises vs control
Meenagh et al., 200437 IA corticosteroid vs placebo
Weiss et al., 200441 Neoprene splint (PFN) vs custom-made
splint (CMS)
Brosseau et al., 200538 Low level laser therapy vs placebo
Stahl et al., 200539 IA corticosteroid vs IA hyaluronate
Wajon et al., 200540 TSS*þ exercise vs SOSy þ exercise
Fuchs et al., 200642 IA hyaluronate vs IA steroid
Michalsen et al., 200643 Leeches vs topical diclofenac
Stange-Rezende et al., 200644 Infrared radiation (IRR) vs control
Roux et al., 200745 IA hyaluronate (once vs twice vs thrice)
Widrig et al., 200746 Topical ibuprofen gel vs arnica gel
Heyworth et al., 200847 IA hylan vs IA corticosteroid vs placebo
*TSS¼ thumb strap splint.
ySOS¼ short opponens splint.(CMC) OA. Eleven RCTs evaluated subjects with interpha-
langeal (proximal interphalangeal joint (PIP) and/or distal
interphalangeal joint (DIP)) OA, but not ﬁrst CMC OA.
Nine RCTs evaluated all three joint areas (PIP, DIP and
ﬁrst CMC).
Only 15 RCTs presented detailed information pertaining
to the number and location of symptomatic hand joints per
treatment group at baseline. This information is important
to include as a clinical descriptive feature of how much pa-
tients are affected by hand OA. Only 19 RCTs speciﬁed the
number and location of evaluated hand joints at the end of
the study. Only 15 RCTs speciﬁed a priori a hand joint site
for efﬁcacy analysis.II
f the hand (N¼ 44)
N
andomized
N
completed
Design Duration
(weeks)
Overall efﬁcacy
594 559 Parallel 4 Lumiracoxib> placebo
19 18 Parallel 6 Strength training>
control
40 35 Parallel 24 Equal
25 25 Cross-over 2 PFN>CMS
88 86 Parallel 6 Equal
52 52 Parallel 24 Equal
40 34 Parallel 6 Equal
56 51 Parallel 26 Equal
32 32 Parallel 8.6 Leeches> diclofenac
45 35 Cross-over 8 IRR> control
42 37 Parallel 12 Equal
204 174 Parallel 3 Equal
60 60 Parallel 26 Equal
1266 D. Mahendira and T. E. Towheed: Systematic review of hand OA trialsEight RCTs did not specify whether one hand or both
hands were evaluated. Seventeen RCTs evaluated one
hand only, whereas 18 RCTs evaluated both hands. Fifteen
RCTs speciﬁed a minimum entry criterion for symptoms
and/or objective ﬁndings, including speciﬁc X-ray criteria
at baseline.
There was a lack of standardization of outcomes across
the 44 RCTs. Moreover, some outcome variables used in
these RCTs have not been validated in OA trials. Pain,
function, and patient global assessments were evaluated
in 38, 35 and 19 RCTs, respectively. Physician global as-
sessments and health-related quality of life were evaluated
in nine and three RCTs, respectively. Examples of outcome
variables used in these trials that have not been validated in
OA trials include joint swelling, joint tenderness, need for
OA related surgery, analgesic usage, sleep quality and
range of motion. A standardized, validated questionnaire
(generic and/or disease speciﬁc) was used for outcome as-
sessment in 18 RCTs. This included the disease speciﬁc
AUSCAN questionnaire81 and Dreiser’s Functional Index82.FEATURES OF TRIAL QUALITYPre-randomization inclusion criteria were clearly speci-
ﬁed in 36 RCTs. Pre-randomization exclusion criteria were
clearly speciﬁed in 30 RCTs. Subjects were blinded in 25
RCTs and investigators were blinded in 29 RCTs. Fifteen
of the 44 RCTs were associated with a pharmaceutical
company or manufacturer. Six RCTs excluded subjects
for protocol violation. Eleven RCTs excluded subjects for
adverse effects. Thirty-three RCTs did not specify as to
whether subjects had prior exposure to the test agents.
Fifteen RCTs controlled for supplementary analgesic usage
or co-intervention during the trial duration. Ten RCTs pre-
sented sample size calculations. Nine RCTs provided
a clearly stated rationale for the chosen dosage of at least
one active agent. Eleven RCTs described the method of
randomization. Fourteen RCTs described the method of
blinding. Seventeen RCTs deﬁned a priori a main outcome
variable. The success of the blinding was only evaluated at
the end of the study in one of the included RCTs. Eighteen
RCTs presented sufﬁciently detailed baseline data allowing
the reader to ensure that the groups were comparable at
baseline. Twenty-four RCTs used appropriate statistical
analyses. Examples of inappropriate statistical analyses
included: (1) using a parametric statistical test for non-
parametric data, (2) stating that a marginally insigniﬁcant
statistical test was still statistically ‘‘signiﬁcant’’, (3) using
a paired statistical test for independent groups, (4) using
multiple comparisons without employing any statistical cor-
rection. For example, one RCT evaluated several outcome
variables, at separate time points, for the right hand, left
hand, both hands, and the dominant hand. Twenty-one
RCTs either had no withdrawals or used an intention-to-
treat analysis. Only four RCTs adequately described the
method used to ensure allocation concealment83.METHODOLOGICAL QUALITY BASED ON JADAD’S SCORESThe median Jadad score for the entire group of RCTs was
3, with a range of 0e5. Twenty-ﬁve RCTs received a score of
1 for being double-blinded. Twenty-nine RCTs received
a score of 1 for providing an adequate description of with-
drawals and drop-outs. All RCTs were randomized as per
the inclusion criteria of the systematic review and therefore
all received a score of 1 for this criterion. The median Jadadscore for the 13 RCTs that were added to this version of the
systematic review was only 2. Thus, it does not appear that
the quality of the more recent hand OA trials has improved.META-ANALYSISA formal meta-analysis could not be performed as most of
the therapiesstudieddidnothavemore thanone identical com-
parison to allow pooling of the data. Also, the studies were too
clinically diverse making a meta-analysis inappropriate.SUMMARY OF RESULTS OF THERAPIESDue to the inherent methodological limitations in these
studies, it is difﬁcult to offer any reliable practical recom-
mendations for the choice of appropriate therapy in subjects
with clinically signiﬁcant hand OA (Tables IeIII). However,
based on these 44 analyzed RCTs, one can conclude that
there is at least some evidence from a published RCT for
the efﬁcacy for the following therapies: trolamine salicylate,
GAGPS, ﬁornal and FIPA, splints for ﬁrst CMC OA, occupa-
tional therapy, dextrose prolotherapy, oral NSAIDs, stinging
nettle leaf, topical capsaicin, vitamin B12 with folate, yoga,
leeches, strength training exercise and spa therapy. At least
some evidence also exists from a published RCT for struc-
tural efﬁcacy in hand OA for the following therapies: chon-
droitin sulfate, chondroitin polysulfate, and GAGPS.Discussion
Results of this systematic review allow for a number of
general conclusions. First, there are few published RCTs
evaluating the wide range of therapies available for hand
OA. However, 13 RCTs were published from August 2004
to February 2008, which is a relative increase from previous
years. Second, RCTs in hand OA are weak methodologi-
cally. The most important issues relate to deﬁciencies in al-
location concealment, inadequate description of the
methods of randomization and blinding, failure to use inten-
tion-to-treat analyses, inappropriate statistical analyses,
and failure to provide sample size calculations. Third,
a number of more speciﬁc methodological limitations re-
lated to hand OA are also apparent. The number and loca-
tion of symptomatic joints per treatment group at baseline
was usually not stated. In addition, the number and location
of evaluated joints per treatment group at the end of study
was also usually not stated. RCTs were often lacking impor-
tant details regarding whether one or both hands were eval-
uated, whether the ﬁrst CMC joint and/or IP joints were
evaluated, and the selection a priori of both a target joint
site (ﬁrst CMC vs IP joints) and a principal outcome mea-
sure for efﬁcacy evaluation. These are some of the issues
that were addressed by the OARSI task force in the recently
published Consensus Guidelines for the Design and Con-
duct of trials in subjects with hand OA83.Conﬂict of interest
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